STING-IN-15 |
Catalog No.GC78685
One-Click Copy Product Info
|
STING-IN-15 is a potent STING inhibitor with an IC50 value of 116nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2912492-05-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
STING-IN-15 is a potent STING inhibitor with an IC50 value of 116nM [1]. STING-IN-15 can be used as a model compound to construct novel STING inhibitors and screen agonists for regulating tumor growth in mice [2].
In vitro, STING-IN-15 treatment (3µM) for 1h significantly suppressed the elevation of TNF-α and IL-6 induced by STING-specific agonist DMXAA in RAW264.7 cells [1].
In vivo, STING-IN-15 treatment via intraperitoneal injection at a dose of 5mg/kg daily for three consecutive days significantly alleviated cisplatin-induced renal inflammatory injury and reduced apoptosis in mice [1].
References:
[1] Shen A, Wang X, Chen Q, et al. Discovery of potent STING inhibitors bearing a difluorobenzodioxol structural motif as potent anti-inflammatory agents[J]. Journal of Medicinal Chemistry, 2025, 68(8): 8907-8932.
[2] Hou S, Chang J, Xing C, et al. Design, synthesis, and biological evaluation of selective sting synergists that enhance cgamp-sting pathway activation without inherent agonist activity[J]. Journal of Medicinal Chemistry, 2025, 68(9): 9407-9430.
| Cell experiment [1]: | |
|
Cell lines |
RAW264.7 cells |
|
Preparation Method |
RAW264.7 cells were grown in high-glucose DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO2. RAW264.7 cells were pretreated with varying doses of STING-IN-15 (0, 0.3, 1, and 3µM) or vehicle for 1h, followed by stimulation with murine STING-specific agonist DMXAA (50μM) for 24h. The secretion levels of TNF-α, IL-6, and IP-10 were measured using ELISA. |
|
Reaction Conditions |
0, 0.3, 1, and 3µM; 1h |
|
Applications |
STING-IN-15 treatment significantly suppressed the elevation of TNF-α, IL-6, and IP-10 induced by DMXAA in RAW264.7 cells in a dose-dependent manner. |
| Animal experiment [1]: | |
|
Animal models |
Male C57BL/6 mice |
|
Preparation Method |
Male C57BL/6 mice (8 weeks old) were housed in standard cages at room temperature (20-26°C) and humidity (40-60%) under a 12/12h light/dark cycle with ad libitum access to autoclaved chow and water. Mice were randomly divided into three groups: vehicle group, cisplatin-model group (10mg/kg), and cisplatin+STING-IN-15 group (5mg/kg/day). Mice were intraperitoneally injected with STING-IN-15 1h prior to cisplatin intraperitoneal injection, then STING-IN-15 was administered intraperitoneally for 2 more days. All mice were euthanized, and kidney tissues were collected for analysis. |
|
Dosage form |
5mg/kg/day for 3 days; i.p. |
|
Applications |
STING-IN-15 treatment alleviated Cisplatin-induced inflammatory injury to the kidneys of mice. |
|
References: |
|
| Cas No. | 2912492-05-6 | SDF | |
| Formula | C20H14F2N4O3 | M.Wt | 396.35 |
| Solubility | DMSO: 100 mg/mL(252.30 mM; Need ultrasonic) | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.523 mL | 12.6151 mL | 25.2302 mL |
| 5 mM | 504.6 μL | 2.523 mL | 5.046 mL |
| 10 mM | 252.3 μL | 1.2615 mL | 2.523 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)